Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 3/20 | 0.52 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Elisartan SCHEMBL1560942 | 1.00 | AGTR1 (0.52) | AGTR1AGTR2PPARGKCNH2 | |
| Elisartan SCHEMBL489079 | 0.99 | AGTR1 (0.53) | AGTR1AGTR2PPARGKCNH2 | |
| Elisartan SCHEMBL489081 | 0.99 | AGTR1 (0.53) | AGTR1AGTR2PPARGKCNH2 | |
| Elisartan SCHEMBL29595840 | 0.99 | AGTR1 (0.52) | AGTR1AGTR2PPARGKCNH2 | |
| Elisartan SCHEMBL615371 | 0.99 | AGTR1 (0.52) | AGTR1AGTR2PPARGKCNH2 | |
| SCHEMBL6130076 | 0.93 | AGTR1 (0.48) | AGTR1AGTR2 | |
| SCHEMBL4609266 | 0.93 | AGTR1 (0.48) | AGTR1AGTR2 | |
| SCHEMBL12990879 | 0.93 | AGTR2 (0.53) | AGTR1AGTR2PPARG | |
| SCHEMBL12991717 | 0.91 | AGTR2 (0.51) | AGTR1AGTR2 | |
| SCHEMBL13771416 | 0.90 | AGTR1 (0.48) | AGTR1AGTR2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176848-A1 | FORTIFIER | TORAY INDUSTRIES, INC., A CORPORATION OF JAPAN (JP) | 2009-07-09 | — | — | US | claimed |
| US-20060217421-A1 | Fortifier | TORAY INDUSTRIES, INC. (JP) | 2006-09-28 | — | — | US | claimed |
| CN-1784235-A | Fortifier | TORAY INDUSTRIES (JP) | 2006-06-07 | — | — | CN | claimed |
| EP-1627638-A1 | FORTIFIER | TORAY INDUSTRIES, INC. (JP) | 2006-02-22 | — | — | EP | claimed |
| EP-1389105-A4 | METHOD OF TREATMENT | MERCK & CO INC (US) | 2005-08-17 | — | — | EP | claimed |
| EP-1389105-A1 | METHOD OF TREATMENT | Merck & Co., Inc. (US) | 2004-02-18 | — | — | EP | claimed |
| US-20030073705-A1 | Method of treatment | SHAHINFAR SHAHNAZ (US) | 2003-04-17 | — | — | US | claimed |
| WO-2002092081-A1 | METHOD OF TREATMENT | MERCK & CO., INC. (US) | 2002-11-21 | — | — | WO | claimed |
| US-6300356-B1 | ADMINISTERING TO A PATIENT IN NEED OF SUCH TREATMENT A THERAPEUTICALLY EFFECTIVE AMOUNT OF AN ANGIOTENSIN II RECEPTOR ANTAGONIST | MERCK & CO., INC. | 2001-10-09 | — | — | US | claimed |
| US-6201002-B1 | ADMINISTERING IMIDAZOLE DERIVATIVE TO TREAT CONGESTIVE HEART FAILURE AND CARDIOVASCULAR DISORDERS | MERCK & CO., INC. | 2001-03-13 | — | — | US | claimed |
| US-20240002440-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS | JPMORGAN CHASE BANK, N.A. | 2024-01-04 | — | — | US | disclosed |
| US-11319346-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | BAUSCH HEALTH IRELAND LIMITED (IE) | 2022-05-03 | — | — | US | disclosed |
| US-20210403508-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | JPMORGAN CHASE BANK, N.A. | 2021-12-30 | — | — | US | disclosed |
| US-11142549-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | BAUSCH HEALTH IRELAND LIMITED (IE) | 2021-10-12 | — | — | US | disclosed |
| US-20200399315-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | JPMORGAN CHASE BANK, N.A. | 2020-12-24 | — | — | US | disclosed |
| WO-2004110368-A2 | COMBINATION THERAPY FOR THE TREATMENT OF HYPERTENSION | MERCK & CO., INC. (US) | 2004-12-23 | — | — | WO | disclosed |
| US-20040116510-A1 | Antihypertensive agent and cholesterol absorption inhibitor combination therapy | NICHTBERGER STEVEN A (US) | 2004-06-17 | — | — | US | disclosed |
| EP-1389105-A1 | METHOD OF TREATMENT | Merck & Co., Inc. (US) | 2004-02-18 | — | — | EP | disclosed |
| US-20030073705-A1 | Method of treatment | SHAHINFAR SHAHNAZ (US) | 2003-04-17 | — | — | US | disclosed |
| WO-2002092081-A1 | METHOD OF TREATMENT | MERCK & CO., INC. (US) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176848-A1 | FORTIFIER | REN, ACE, PTGER1 | AGTR1 10/4885AGTR2 39/4885PPARG 213/4885 |
| US-20210403508-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | AGTR1 317/4885AGTR2 480/4885PPARG 1675/4885 |
| US-11142549-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | GUCY1A1, GUCY1A2, GUCY1B1 | AGTR1 317/4885AGTR2 480/4885PPARG 1675/4885 |
| US-20200399315-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | AGTR1 317/4885AGTR2 480/4885PPARG 1675/4885 |
| US-11319346-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | GUCY1A1, GUCY1A2, GUCY1B1 | AGTR1 317/4885AGTR2 480/4885PPARG 1675/4885 |
| US-20060217421-A1 | Fortifier | REN, PTGER1, GPR132 | AGTR1 8/4885AGTR2 22/4885PPARG 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.